Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
238 participants
OBSERVATIONAL
2015-01-01
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules.
We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC).
No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm).
This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction
NCT05078801
Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma
NCT04791735
Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer
NCT03679338
Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma
NCT00797121
Cholangioscopy or Conventional Techniques for Indeterminate Biliary Stenosis
NCT04840537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All thermoablation procedures were performed percutaneously under ultrasound or CT guidance, with ou without artificial pneumothorax or ascites, with ou without lipiodol marked.
Purposes:
* Tumor response upon mRECIST criteria
* Progression-free survival
* Overall survival
* Local tumor progression
* Distent liver progression
* Prognostic factors
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCLC0 or A
* Measurable targets according to mRECIST v1.1
* Child A or B7 cirrhosis
* HCC \< 4 cm, \< 3 nodules, Age ≥ 18 years
* No extrahepatic metastasis, no vascular invasion
* Performance status 0 or 1
* Thrombocytes ≥ 50 000/mm3, TP \> 50%
Exclusion Criteria
* Lobar/main portal venous thrombus
* Abundant ascites
* Antecedent of bilio-digestive anastomosis or endoscopic sphincterotomy
* Combined treatment with embolization or chemo-embolization
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BORIS GUIU, PU-PH
Role: STUDY_DIRECTOR
University Hospital, Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uhmontpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL17_0436
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.